| ADT | Androgen deprivation therapy |
| AE | Adverse event |
| AKT | Ak strain transforming |
| AR | Androgen receptor |
| ARID1A | AT-rich interaction domain 1A |
| ASH2L | ASH2 like, histone lysine methyltransferase complex subunit |
| ATRA | All-trans retinoic acid |
| BAX | Bcl2-associated X |
| BCa | Breast cancer |
| BCL2 | B-cell lymphoma 2 |
| BET | Bromodomain and extraterminal |
| BETi | Bromodomain and extraterminal inhibitor |
| BMP7 | Bone Morphogenetic Protein 7 |
| BRCA1/2 | Breast cancer gene 1 or 2 |
| BRD | Bromodomain-containing |
| BRDT | Bromodomain testis-specific protein |
| CBP | CREB-binding protein |
| CBR | Clinical benefit rate |
| CDH1 | Cadherin 1 |
| CDK4/6 | Cyclin-dependent kinase 4/6 |
| CDKN2A | Cyclin-dependent kinase inhibitor 2A |
| CR | Complete response |
| CRPC | Castration-resistant prostate cancer |
| CRR | Clinical response rate |
| CSC | Cancer stem cell |
| CTC | Circulating tumor cell |
| CTCAE | Common Terminology Criteria for Adverse Events |
| CTCL | Cutaneous T-cell lymphoma |
| CtDNA | Circulating tumor DNA |
| DLT | Dose-limiting toxicity |
| DNA | Deoxyribonucleic acid |
| DNMT | DNA methyltransferase |
| DNMTi | DNA methyltransferase inhibitor |
| DOR | Duration of response |
| ECa | Endometrial cancer |
| EED | Embryonic ectoderm development |
| EEDi | Embryonic ectoderm development inhibitor |
| EGFR | Epidermal growth factor receptor |
| EHMT2 | Euchromatic histone lysine N-methyltransferase 2 |
| ER | Estrogen receptor (protein) |
| ESR1 | Estrogen receptor 1 (gene) |
| EZH2 | Enhancer of zeste homolog 2 |
| EZH2i | Enhancer of zeste homolog 2 inhibitor |
| FDA | Food and Drug Administration |
| GADD45A | DNA damage-inducible alpha |
| GSTP1 | Glutathione S-transferase Pi 1 |
| H3K23ac | Histone 3 lysine 23 acetylation |
| H3K27me3 | Histone 3 lysine 27 trimethylation |
| H3K4me2/3 | Histone 3 lysine 4 di-/trimethylation |
| H3K9me | Histone 3 lysine 9 methylation |
| HAT | Histone acetyltransferase |
| HDAC | Histone deacetylase |
| HDACi | Histone deacetylase inhibitor |
| HER2 | Human epidermal growth factor receptor 2 |
| HMA | Hypomethylating agent |
| HOXD3 | Homeobox D3 |
| HR | Hormone receptor |
| HRBC | Hormone-resistant breast cancer |
| Hsp90 | Heat shock protein 90 (gene) |
| KAT6A/B | Lysine acetyltransferase 6 A/B |
| KAT6i | Lysine acetyltransferase 6 inhibitor |
| KDM | Lysine demethylase |
| KDM1A | Lysine demethylase 1A |
| KDM1Ai | Lysine demethylase 1A inhibitor |
| KLK3 | Kallikrein-related peptidase 3 |
| KMT | Lysine methyltransferase |
| LINE-1 | Long Interspersed Nuclear Element-1 |
| LSD1 | Lysine-specific demethylase 1 |
| mCRPC | Metastatic castration-resistant prostate cancer |
| MGMT | O6-methylguanine-DNA methyltransferase |
| MLH1 | MutL homolog 1 |
| MPA | Medroxyprogesterone acetate |
| MTD | Maximum tolerated dose |
| mTOR | Mechanistic target of rapamycin kinase |
| NF-κβ | Nuclear factor kappa-light-chain-enhancer of activated B cells |
| NIS | Sodium iodide symporter |
| NSD2 | Nuclear Receptor Binding SET Domain Protein 2 |
| ORR | Overall response rate |
| OS | Overall survival |
| OvCa | Ovarian cancer |
| P53 | Tumor protein 53 |
| PAEP | Progestagen-Associated Endometrial Protein |
| PARP | Poly (ADP-ribose) polymerase |
| PCa | Prostate cancer |
| pCR | Pathological complete response |
| PD-1 | Programmed cell death 1 |
| PD-L1 | Programmed Death-Ligand 1 |
| PFS | Progression-free survival |
| PFS1 | First-stage progression-free survival |
| PGR | Progesterone receptor (gene) |
| PIK3CA | Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
| PR | Progesterone receptor (protein) |
| PRC2 | Polycomb repressive complex 2 |
| PSA | Prostate-specific antigen |
| PSA-DT | PSA doubling time |
| PSMA | Prostate-specific membrane antigen |
| PTEN | Phosphatase and TENsin homolog deleted on chromosome 10 |
| RAI | Radioactive-iodine therapy |
| RARβ | Retinoic acid receptor β |
| RASSF1A | Ras association domain family protein 1 isoform A |
| RECIST | Response Evaluation Criteria in Solid Tumors |
| RNA | Ribonucleic acid |
| rPFS | Radiographic PFS |
| RUNX3 | Runt-related transcription factor 3 |
| SAE | Serious adverse event |
| SASP | Senescence-Associated Secretory Phenotype |
| SERM | Selective Estrogen Receptor Modulator |
| SET | Su(var)3–9, Enhancer of zeste, and Trithorax |
| SLC5A8 | Solute carrier family 5 member 8 |
| SWF/SNF | Switch/Sucrose Non-Fermentable |
| TCa | Thyroid cancer |
| Tg | Thyroglobulin |
| TGF-βRII | Transforming growth factor beta receptor type II |
| TH | Thyroid hormone |
| TIL | Tumor-infiltrating lymphocyte |
| TME | Tumor microenvironment |
| TNBC | Triple-negative breast cancer |
| TPO | Thyroperoxidase |
| TSG | Tumor suppressor gene |
| TSH | Thyroid stimulating hormone |
| TSHR | TSH receptor |
| TTF-1 | Thyroid transcription factor-1 |
| VPA | Valproic acid |
| ZEB1 | Zinc Finger E-box-Binding Homeobox 1 |